Randhawa Simrat, EVP and Head of R&D at Dianthus Therapeutics ($DNTH), sold about $7.4 million in company shares across four open market transactions over the past year. The most recent sale occurred on November 14, 2025. These sales rank 1,436th among nearly 12,000 individual insiders in our database, where the average is $8.6 million across 6.4 transactions. Simrat made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | S | Common Stock | 33830 | $81.48 | 0.0000 | 42,876,015 | 100.00% | 0.08% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 8332 | $0.00 | 54,174.0000 | 42,876,015 | 13.33% | 0.02% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 5000 | $0.00 | 71,184.0000 | 42,876,015 | 6.56% | 0.01% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 12500 | $0.00 | 106,250.0000 | 42,876,015 | 10.53% | 0.03% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 7998 | $0.00 | 3,998.0000 | 42,876,015 | 66.67% | 0.02% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 7998 | $8.44 | 7,998.0000 | 42,876,015 | 9999.99% | 0.02% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 5000 | $17.88 | 12,998.0000 | 42,876,015 | 62.52% | 0.01% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 8332 | $21.77 | 21,330.0000 | 42,876,015 | 64.10% | 0.02% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 12500 | $22.07 | 33,830.0000 | 42,876,015 | 58.60% | 0.03% |
| Feb. 3, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 42,876,015 | 9999.99% | 0.35% |
| Nov. 13, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 83978 | $0.00 | 11,996.0000 | 42,876,015 | 87.50% | 0.20% |
| Nov. 14, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 40287 | $0.00 | 76,184.0000 | 42,876,015 | 34.59% | 0.09% |
| Nov. 14, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 37494 | $0.00 | 62,506.0000 | 42,876,015 | 37.49% | 0.09% |
| Nov. 14, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 31250 | $0.00 | 118,750.0000 | 42,876,015 | 20.83% | 0.07% |
| Nov. 13, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Stock Option (Right to Buy) | 3529 | $0.00 | 116,471.0000 | 42,876,015 | 2.94% | 0.01% |
| Nov. 13, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 83978 | $8.44 | 87,978.0000 | 42,876,015 | 2099.45% | 0.20% |
| Nov. 13, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 3529 | $17.88 | 91,507.0000 | 42,876,015 | 4.01% | 0.01% |
| Nov. 13, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | S | Common Stock | 26166 | $35.80 | 65,341.0000 | 42,876,015 | 28.59% | 0.06% |
| Nov. 13, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | S | Common Stock | 42765 | $37.04 | 22,576.0000 | 42,876,015 | 65.45% | 0.10% |
| Nov. 13, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | S | Common Stock | 18576 | $37.72 | 4,000.0000 | 42,876,015 | 82.28% | 0.04% |
| Nov. 14, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 40287 | $17.88 | 44,287.0000 | 42,876,015 | 1007.18% | 0.09% |
| Nov. 14, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 37494 | $21.77 | 81,781.0000 | 42,876,015 | 84.66% | 0.09% |
| Nov. 14, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | M | Common Stock | 31250 | $22.07 | 113,031.0000 | 42,876,015 | 38.21% | 0.07% |
| Nov. 14, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | EVP, Head of R&D | S | Common Stock | 109031 | $38.14 | 4,000.0000 | 42,876,015 | 96.46% | 0.25% |
| Sept. 23, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | CHIEF MEDICAL OFFICER | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 32,125,179 | 9999.99% | 0.19% |
| Feb. 3, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | CHIEF MEDICAL OFFICER | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | CHIEF MEDICAL OFFICER | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 24, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Randhawa Simrat | CHIEF MEDICAL OFFICER | A | Stock Option (Right to Buy) | 120000 | $0.00 | 120,000.0000 | 0 | 9999.99% | 0.00% |